Although early trials of dual VEGF and EGFR inhibition were encouraging (39, 40), more recent trials in unselected populations of VEGF/EGFR inhibitors, such as vandetanib, do not support this approach in the management of advanced NSCLC (41). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.